Abstract
tial response) vs 80% of patients in the other groups. A median survival of 48 months was observed in patients with low-risk biomarkers vs 25 months in patients with high-risk biomarkers (P=.18). Conclusions: In our data set of advanced laryngeal cancer patients, p53 and Bcl-xL together define groups with different risk profiles. Tumor expression of low p53 and low Bcl-xL is a strong predictor of larynx preservation in patients treated with induction chemotherapy followed by radiation therapy in responding tumors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Archives of Otolaryngology - Head and Neck Surgery
Paper Title
Journal
Date
